Concluding one of the longest merger reviews in history, on September 4, Judge Richard Leon, District Judge for the District of Columbia, issued his final ruling in United States v. CVS Health, approving the proposed...more
9/5/2019
/ Aetna ,
AIDS ,
Antitrust Provisions ,
Competition ,
Corporate Sales Transactions ,
CVS ,
Department of Justice (DOJ) ,
Evidentiary Hearings ,
Final Judgment ,
Health Insurance ,
HIV ,
Medicare Part D ,
Pharmacies ,
Pharmacy Benefit Manager (PBM) ,
Prescription Drug Coverage ,
Public Interest ,
Regulatory Standards ,
Settlement ,
Tunney Act
The District of Columbia District Court has again deferred its decision regarding whether to approve the merger between CVS Health and Aetna, a $69 billion transaction that was first announced back in December 2017. ...more
4/11/2019
/ Aetna ,
Antitrust Provisions ,
Competition ,
CVS ,
Department of Justice (DOJ) ,
Health Insurance ,
Joint Venture ,
Medicare Part D ,
Merger Controls ,
Pharmaceutical Industry ,
Pharmacies ,
Popular
In a filing with the Securities and Exchange Commission on November 26, CVS Health Corporation announced that it has received all of the regulatory approvals necessary to complete its acquisition of Aetna and that the...more
The United States Department of Justice Antitrust Division announced on October 10, 2018, that it was conditionally approving the CVS/Aetna merger, a $69 billion transaction that combines the nation’s largest retail pharmacy...more
10/12/2018
/ Aetna ,
Antitrust Division ,
Antitrust Provisions ,
Competition ,
CVS ,
Department of Justice (DOJ) ,
Health Insurance ,
Medicare Part D ,
Pharmacies ,
Popular ,
Regulatory Standards ,
Retailers
Two pieces of related legislation that would prohibit so called “gag clauses” in contracts between pharmacists and health plans and pharmacy benefit managers (PBM’s) have been passed by both the Senate and the House....more
10/9/2018
/ Contract Terms ,
Disclosure ,
Drug Pricing ,
Health Insurance ,
Legislative Agendas ,
Medicare Advantage ,
Medicare Part D ,
Out-of-Pocket Expenses ,
Pending Legislation ,
Pharmaceutical Industry ,
Pharmacies ,
Pharmacy Benefit Manager (PBM) ,
Prescription Drugs ,
Trump Administration